Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 214

1.

Oral microbiota and Alzheimer's disease: Do all roads lead to Rome?

Sureda A, Daglia M, Argüelles Castilla S, Sanadgol N, Fazel Nabavi S, Khan H, Belwal T, Jeandet P, Marchese A, Pistollato F, Forbes-Hernandez T, Battino M, Berindan-Neagoe I, D'Onofrio G, Nabavi SM.

Pharmacol Res. 2019 Nov 30:104582. doi: 10.1016/j.phrs.2019.104582. [Epub ahead of print] Review.

PMID:
31794871
2.

Prognostic Value of MiR-21: An Updated Meta-Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC).

Irimie-Aghiorghiesei AI, Pop-Bica C, Pintea S, Braicu C, Cojocneanu R, Zimța AA, Gulei D, Slabý O, Berindan-Neagoe I.

J Clin Med. 2019 Nov 21;8(12). pii: E2041. doi: 10.3390/jcm8122041. Review.

3.
4.

The Role of Nrf2 Activity in Cancer Development and Progression.

Zimta AA, Cenariu D, Irimie A, Magdo L, Nabavi SM, Atanasov AG, Berindan-Neagoe I.

Cancers (Basel). 2019 Nov 8;11(11). pii: E1755. doi: 10.3390/cancers11111755. Review.

5.

Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms.

Braicu C, Gulei D, Raduly L, Harangus A, Rusu A, Berindan-Neagoe I.

Mol Aspects Med. 2019 Dec;70:90-105. doi: 10.1016/j.mam.2019.10.007. Epub 2019 Nov 6. Review.

PMID:
31703947
6.

Long Non-coding RNAs in Myeloid Malignancies.

Zimta AA, Tomuleasa C, Sahnoune I, Calin GA, Berindan-Neagoe I.

Front Oncol. 2019 Oct 18;9:1048. doi: 10.3389/fonc.2019.01048. eCollection 2019. Review.

7.

Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.

Braicu C, Buiga R, Cojocneanu R, Buse M, Raduly L, Pop LA, Chira S, Budisan L, Jurj A, Ciocan C, Magdo L, Irimie A, Dobrota F, Petrut B, Berindan-Neagoe I.

J Exp Clin Cancer Res. 2019 Oct 29;38(1):433. doi: 10.1186/s13046-019-1406-6.

8.

Molecular Links between Central Obesity and Breast Cancer.

Zimta AA, Tigu AB, Muntean M, Cenariu D, Slaby O, Berindan-Neagoe I.

Int J Mol Sci. 2019 Oct 28;20(21). pii: E5364. doi: 10.3390/ijms20215364. Review.

9.

A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.

Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I.

Cancers (Basel). 2019 Oct 22;11(10). pii: E1618. doi: 10.3390/cancers11101618. Review.

10.

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.

Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.

J BUON. 2019 Jul-Aug;24(4):1538-1543.

11.

Nanoscale delivery systems for microRNAs in cancer therapy.

Boca S, Gulei D, Zimta AA, Onaciu A, Magdo L, Tigu AB, Ionescu C, Irimie A, Buiga R, Berindan-Neagoe I.

Cell Mol Life Sci. 2019 Oct 21. doi: 10.1007/s00018-019-03317-9. [Epub ahead of print] Review.

PMID:
31637450
12.

SIRT1 in the Development and Treatment of Hepatocellular Carcinoma.

Farcas M, Gavrea AA, Gulei D, Ionescu C, Irimie A, Catana CS, Berindan-Neagoe I.

Front Nutr. 2019 Sep 25;6:148. doi: 10.3389/fnut.2019.00148. eCollection 2019. Review.

13.

The extensive role of miR-155 in malignant and non-malignant diseases.

Gulei D, Raduly L, Broseghini E, Ferracin M, Berindan-Neagoe I.

Mol Aspects Med. 2019 Dec;70:33-56. doi: 10.1016/j.mam.2019.09.004. Epub 2019 Sep 23. Review.

PMID:
31558293
14.

Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia.

Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghea M, Bojan A, Trifa A, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C, Dima D.

Front Oncol. 2019 Sep 6;9:872. doi: 10.3389/fonc.2019.00872. eCollection 2019.

15.

CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia.

Tatar AS, Jurj A, Tomuleasa C, Florea A, Berindan-Neagoe I, Cialla-May D, Popp J, Astilean S, Boca S.

Colloids Surf B Biointerfaces. 2019 Dec 1;184:110478. doi: 10.1016/j.colsurfb.2019.110478. Epub 2019 Aug 30.

PMID:
31541890
16.

GLS2 is protumorigenic in breast cancers.

Dias MM, Adamoski D, Dos Reis LM, Ascenção CFR, de Oliveira KRS, Mafra ACP, da Silva Bastos AC, Quintero M, de G Cassago C, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG.

Oncogene. 2019 Sep 20. doi: 10.1038/s41388-019-1007-z. [Epub ahead of print]

PMID:
31541193
17.

Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development.

Zimta AA, Schitcu V, Gurzau E, Stavaru C, Manda G, Szedlacsek S, Berindan-Neagoe I.

Environ Res. 2019 Nov;178:108700. doi: 10.1016/j.envres.2019.108700. Epub 2019 Aug 28. Review.

PMID:
31520827
18.

MicroRNA profiling in kidney in pigs fed ochratoxin A contaminated diet.

Marin DE, Braicu C, Dumitrescu G, Pistol GC, Cojocneanu R, Neagoe IB, Taranu I.

Ecotoxicol Environ Saf. 2019 Nov 30;184:109637. doi: 10.1016/j.ecoenv.2019.109637. Epub 2019 Sep 6.

PMID:
31499447
19.

Progress in Research on the Role of Flavonoids in Lung Cancer.

Zanoaga O, Braicu C, Jurj A, Rusu A, Buiga R, Berindan-Neagoe I.

Int J Mol Sci. 2019 Sep 2;20(17). pii: E4291. doi: 10.3390/ijms20174291. Review.

20.

Hydrogels Based Drug Delivery Synthesis, Characterization and Administration.

Onaciu A, Munteanu RA, Moldovan AI, Moldovan CS, Berindan-Neagoe I.

Pharmaceutics. 2019 Aug 23;11(9). pii: E432. doi: 10.3390/pharmaceutics11090432. Review.

Supplemental Content

Loading ...
Support Center